Camp4 Therapeutics FY25 GAAP EPS missed expectations, but ended the year with a robust cash position. Check out why CAMP ...
Regenxbio (RGNX) hit by FDA CRL for RGX-121; valuation discount, cash runway to 2027, risks vs RGX-202 upside. Click here to ...
Image courtesy by QUE.com China is accelerating its push into next-generation robotics with a new wave of national standards ...
This study presents valuable findings for identifying biotypes of depression patients using white matter measures, which are under-utilised and under-appreciated in current biological and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results